BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 50,000 shares, a decrease of 62.1% from the September 30th total of 132,100 shares. Based on an average daily volume of 821,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.8% of the shares of the stock are sold short.
BioCardia Stock Up 0.8 %
Shares of BioCardia stock opened at $2.42 on Monday. The stock has a market cap of $4.41 million, a price-to-earnings ratio of -0.34 and a beta of 1.26. BioCardia has a twelve month low of $1.96 and a twelve month high of $23.25. The company’s fifty day moving average is $2.75 and its 200 day moving average is $3.64.
BioCardia (NASDAQ:BCDA – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). As a group, equities analysts anticipate that BioCardia will post -5.06 earnings per share for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Stock Report on BCDA
BioCardia Company Profile
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Featured Articles
- Five stocks we like better than BioCardia
- Breakout Stocks: What They Are and How to Identify Them
- Amazon: Why Analysts Think It’s A Solid Buy Ahead Of Earnings
- What are earnings reports?
- NextEra’s Diverse Business Is Set to Win As Energy Demand Rises
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.